SCHEMBL6206526

SCHEMBL6206526

CCc1ccc(Nc2c(-c3nnc(NC(CN4CCOCC4)c4ccccc4)o3)ccc(F)c2F)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 1/20 0.39
PDCD1 Q15116 1/20 0.37
CD274 Q9NZQ7 1/20 0.37
SCN1A P35498 2/20 0.36
SCN5A Q14524 2/20 0.36
SCN8A Q9UQD0 2/20 0.36
MEN1 O00255 6/20 0.36
KMT2A Q03164 6/20 0.36
ATM Q13315 3/20 0.36
CHRNA7 P36544 4/20 0.35
KCNH2 Q12809 3/20 0.35
CDC7 O00311 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
DBF4 Q9UBU7 1/20 0.34
CHRNA1 P02708 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CHRNB2 P17787 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6398804 0.86 CDC7 (0.37) SCN1ASCN5ASCN8ACDC7CCNE1
SCHEMBL6399220 0.82 CHRNA7 (0.43) MAP3K8CHRNA7KCNH2CHRNA1CYP1A2
SCHEMBL6403620 0.80 CHRNA7 (0.48) MAP3K8CHRNA7KCNH2CHRNA1CYP1A2
SCHEMBL6399685 0.79 ELANE (0.36) CYP3A4MAP2K2MAP2K1
SCHEMBL6207124 0.79 CHRNA7 (0.42) MAP3K8CHRNA7KCNH2CHRNA1CYP1A2
SCHEMBL6208204 0.77 LMNA (0.44)
SCHEMBL6206984 0.77 MAP3K8 (0.36) MAP3K8CHRNA7KCNH2CHRNA1CYP1A2
SCHEMBL6405809 0.77 KAT2B (0.30)
SCHEMBL6397573 0.77 RXFP1 (0.33) PDCD1CD274MAP2K2MAP2K1
SCHEMBL6206805 0.76 BCHE (0.39) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578736-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES Warner-Lambert Company LLC (US) 2005-09-28 EP claimed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US claimed
WO-2004056789-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES WARNER-LAMBERT COMPANY LLC (US) 2004-07-08 WO claimed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004186-A1 MEK inhibiting compounds MAPK1, MAP3K1, MAPK3 MAP3K8 18/4885PDCD1 191/4885CD274 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.